We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal

Download Mobile App




Cartridge-Based Antigen Testing System Delivers PCR Equivalent Performance at Half the Price

By HospiMedica International staff writers
Posted on 19 May 2023
Print article
Image: The first-in-class diagnostic platform technology will enable faster and more precise diagnosis (Photo courtesy of Burst Diagnostics)
Image: The first-in-class diagnostic platform technology will enable faster and more precise diagnosis (Photo courtesy of Burst Diagnostics)

A new first-in-class diagnostic platform technology that is transitioning from a working prototype to a commercial system is soon set to disrupt the point-of-care diagnostics industry.

Zymo Research (Irvine, CA, USA) has joined hands with Burst Diagnostics (Fort Collins, CO, USA) to create a pioneering diagnostic platform technology. This first-in-class diagnostic platform technology has the potential to deliver unmatched sensitivity and never-seen-before multiplexing abilities in antigen-based point-of-care testing. The platform is based on a novel microfluidic cartridge that is capable of miniaturizing and integrating all the traditional steps commonly carried out in a clinical lab environment (including washing and signal amplification) into a compact, sturdy, and electricity-free hand-held device.

The cartridge-based antigen testing system promises performance on par with PCR-based testing but at half the cost. The ELISA system bears a striking resemblance to a rapid antigen test but comes with an integrated high-sensitivity chemiluminescence reader. Burst plans to offer rapid immunoassays with fewer false negatives than standard rapid antigen tests used in point-of-care situations while also providing these results at lower costs than lab-based tests. Burst is planning further studies and is aiming to submit an application for authorization from the US Food and Drug Administration for its inaugural test and reader by the first quarter of 2024. The company's first offering is likely to be a multiplex test for COVID-19, influenza A and B, and RSV. Additionally, Burst is in the initial stages of developing tests for sexually transmitted infections and strep throat.

"The tests we are building are simple, convenient, and inexpensive like rapid antigen tests but capable of producing laboratory-quality data with the level of sensitivity and accuracy previously exclusive to central lab run tests," said Dr. Charles Henry, Founder and CEO of Burst Diagnostics.

"We have a radical new technology and with it, we will challenge the limitations associated with antigen tests as we know them," added Dr. Rose Nash, Chief Operating Officer and Scientist at Burst Diagnostics.

"The creation of this advanced and ultra-sensitive technology will transform the industry and significantly impact the healthcare sector. It will enable faster and more precise diagnosis and treatment of diseases," said Dr. Larry Jia, Founder and CEO of Zymo Research.

Related Links:
Zymo Research
Burst Diagnostics 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Rectangular Top Imaging-Pain Management Table
CFPM302

Print article

Channels

Critical Care

view channel
Image: The lithium-ion battery has entirely stretchable components and stable charging and discharging capacity over time (Photo courtesy of ACS Energy Letters 2024, DOI: 10.1021/acsenergylett.4c01254)

Fully Stretchable Solid Lithium-Ion Battery Paves Way For Flexible Wearable and Implantable Devices

Electronics designed to bend and stretch require batteries that possess the same flexible characteristics. Many attempts to construct such batteries have utilized conductive fabric woven into expandable... Read more

Surgical Techniques

view channel
Image: The ExcelsiusFlex and ACTIFY 3D Total Knee System have been granted FDA 510(k) clearance (Photo courtesy of Globus Medical)

New Robotic Navigation Platform Provides Surgeons Best-In-Class Solution for Orthopedic Treatment

Globus Medical (Audubon, PA, USA) has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new robotic navigation platform, ExcelsiusFlex, tailored for total knee arthroplasty... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Business

view channel
Image: The Innovalve transseptal delivery system is designed to enable safe deployment of the Innovalve implant (Photo courtesy of Innovalve Bio)

Edwards Lifesciences Acquires Sheba Medical’s Innovalve Bio Medical

Edwards Lifesciences (Irvine, CA, USA), a leading company in medical innovations for structural heart disease and critical care, has acquired Innovalve Bio Medical LTD. (Ramat Gan, Israel), an early-stage... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.